ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest Capital Structure Improved as Total Outstanding Common Stock Reduced By Approximately 19% RAMSEY, N.J. and BOCA RATON, FL.

ADMA Biologics Retires Approximately

8.6 Million Shares Previously Issued to Biotest

Capital Structure Improved as Total Outstanding Common Stock

Reduced By Approximately 19%

RAMSEY, N.J. and BOCA RATON, FL., - May 14, 2018 -

ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") announced today that it has negotiated the

receipt and immediate retirement of approximately 8.6 million shares of its non-voting common stock previously issued to Biotest

Pharmaceuticals Corporation ("BPC") and its former parent, Biotest AG (collectively, "Biotest"), as consideration

for the waiver and release of certain ADMA rights under the Master Purchase and Sale Agreement, dated as of January 21, 2017, among

ADMA and Biotest and certain of their subsidiaries (the "Master Purchase Agreement").

"We believe the retirement of the non-voting common stock

simplifies ADMA's capital structure, while reducing our total common stock outstanding by approximately 19%, from 45.3 million

shares to 36.7 million shares," stated Adam Grossman, ADMA's President and Chief Executive Officer.

Mr. Grossman further stated, "We are very pleased to assist

Biotest as our partner, who is finalizing its pending divestiture of U.S. assets, and return this value to our stockholders."

"The total consideration ADMA paid for the Biotest Therapy

Business Unit in June 2017 comprised of approximately 12.9 million shares of ADMA's common stock, and ADMA's two plasma

collection centers which are planned to be transferred to BPC on January 1, 2019," stated Brian Lenz, ADMA's Chief

Under the terms of a Share Transfer, Amendment and Release Agreement:

The description of the release and termination provisions, as

well as additional agreements in this press release, are not all inclusive and, as such, the statements in this press release are

qualified in their entirety by reference to the description of the Share Transfer, Amendment and Release Agreement which will be

included in a Current Report on Form 8-K to be filed by ADMA with the Securities and Exchange Commission. You can view our public

filings, including the referenced Form 8-K by visiting our website at www.admabiologics.com

ADMA Biologics, Inc. (ADMA)

ADMA is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based

biologics for the treatment of Primary Immune Deficiency Disease ("PIDD") and the prevention and treatment of certain

infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient

populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised

individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for other medical reasons.

ADMA has received U.S. Patents 9,107,906, 9,714,283 and 9,815,886 related to certain aspects of its lead product candidate, RI-002.

For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",

"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may

predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate,"

"project," "intend," "forecast," "target," "anticipate," "plan,"

"planning," "expect," "believe," "will," "is likely," "will likely,"

"should," "could," "would," "may," or, in each case, their negative, or words or expressions

of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop,

manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products,

the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products

and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party vendors

and the U.S. Food and Drug Administration (the "FDA") in furtherance of and progress towards an approval of our Biologics

License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely

manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe

within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty

plasma-based biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or

other indications, our ability to realize increased prices for plasma growth in the plasma collection industry and our expectations

for future capital requirements. Actual events or results may differ materially from those described in this document due to a

number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the

forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties

inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation

or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if

at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking

statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks,

uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from

any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties

described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q

and 8-K, and any amendments thereto.

Vice President and Chief Financial Officer |201-478-5552 | www.admabiologics.com

INVESTOR RELATIONS CONTACT:

Managing Director, LifeSci Advisors, LLC | 212-915-2568 |